Chemotherapy with a combination of irinotekan and cis- or carboplatin in first-line treatment of small-cell lung cancer

Abstract

We had been interested in treatment efficiency, time until progression, undesirable side-effects and total survival rate/time. Conclusion: treatment outcomes comparable with other schemes.

Keywords

• Chemotherapy
• combination
• irinotekan
• carboplatin
• first-line
• treatment
• small-cell
• cancer